Wechselwirkungen von Deferipron

Deferipron (Ferriprox), ein Eisenpräparat, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 28 dokumentierte Wechselwirkungen: 7 schwerwiegende, 16 mittelschwere, 5 geringfügige und 0, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (7)

  • DiclofenacNSARSchwerwiegend

    Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (Fachinformation zu Deferipron, Arzneimittelwechselwirkungen)

  • Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (Fachinformation zu Deferipron, Arzneimittelwechselwirkungen)

  • MariendistelPflanzliche Mittel und NahrungsergänzungSchwerwiegend

    Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (Fachinformation zu Deferipron, Arzneimittelwechselwirkungen)

  • MethyldopaAntihypertensivumSchwerwiegend

    Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. (Fachinformation zu Methyldopa, Arzneimittelwechselwirkungen)

  • ProbenecidSchwerwiegend

    Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (Fachinformation zu Deferipron, Arzneimittelwechselwirkungen)

  • Effect of Other Drugs on FERRIPROX UDP-Glucuronosyltransferases (UGT) Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with FERRIPROX [ see Dosage and Administration ( 2.2 ) , Adverse Reactions ( 6.1 ), Clinical Pharmacology ( 12.3 ) ] . (Fachinformation zu Deferipron, Arzneimittelwechselwirkungen)

  • RisedronsäureBisphosphonatSchwerwiegend

    Calcium supplements, antacids, magnesium-based supplements or laxatives, and iron preparations interfere with the absorption of Risedronate sodium delayed-release and should not be taken together. (Fachinformation zu Risedronsäure, Arzneimittelwechselwirkungen)

Mittelschwere Wechselwirkungen (16)

  • Antazida (Tums, Maalox, Mylanta)Rezeptfreies PräparatMittelschwer

    Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between FERRIPROX and other medications (e.g., antacids), or supplements containing these polyvalent cations [see Dosage and Administration ( 2.2 ) ] . (Fachinformation zu Deferipron, Arzneimittelwechselwirkungen)

  • CarbidopaMittelschwer

    Carbidopa and iron salts or multivitamins containing iron salts should be coadministered with caution. (Fachinformation zu Carbidopa, Arzneimittelwechselwirkungen)

  • Carbidopa und Levodopadopaminerges ArzneimittelMittelschwer

    Dopamine D2 receptor antagonists, isoniazid, iron salts, and high-protein diet may reduce the effectiveness of DUOPA ( 7.3 , 7.4 , 7.5 ) (Fachinformation zu Carbidopa und Levodopa, Arzneimittelwechselwirkungen)

  • Carbidopa, Levodopa und Entacapondopaminerges ArzneimittelMittelschwer

    • Dopamine D2 receptor antagonists, isoniazid, phenytoin, papaverine and iron salts: may reduce efficacy of Carbidopa, levodopa and entacapone tablets ( 7.5 , 7.6 , 7.7 , 7.8 , 7.9 ) • Drugs that interfere with biliary excretion, glucuronidation and intestinal beta-glucuronidase: dose adjustment of Carbidopa, levodopa and entacapone tablets may be required (… (Fachinformation zu Carbidopa, Levodopa und Entacapon, Arzneimittelwechselwirkungen)

  • CefdinirCephalosporinMittelschwer

    Iron Supplements and Foods Fortified With Iron: Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO 4 ) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively. (Fachinformation zu Cefdinir, Arzneimittelwechselwirkungen)

  • DexlansoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Dexlansoprazol, Arzneimittelwechselwirkungen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitamins cation-containing antacids or laxatives sucralfate buffered medications ↓ elvitegravir Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours. (Fachinformation zu Elvitegravir, Cobicistat, Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

  • EsomeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (Fachinformation zu Esomeprazol, Arzneimittelwechselwirkungen)

  • LansoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Lansoprazol, Arzneimittelwechselwirkungen)

  • Levodopadopaminerges ArzneimittelMittelschwer

    Dopamine D2 antagonists, isoniazid, and iron salts: May reduce the effectiveness of INBRIJA ( 7.2 , 7.3 ) (Fachinformation zu Levodopa, Arzneimittelwechselwirkungen)

  • Naproxen und EsomeprazolNSARMittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, mycophenoloate mofetil, ketoconazole) Clinical Impact: Esomeprazole magnesium can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole magnesium is an enantiomer,… (Fachinformation zu Naproxen und Esomeprazol, Arzneimittelwechselwirkungen)

  • NatriumhydrogencarbonatAntazidumMittelschwer

    Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between FERRIPROX and other medications (e.g., antacids), or supplements containing these polyvalent cations [see Dosage and Administration ( 2.2 ) ] . (Fachinformation zu Deferipron, Arzneimittelwechselwirkungen)

  • OmeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Omeprazol, Arzneimittelwechselwirkungen)

  • Omeprazol und NatriumhydrogencarbonatProtonenpumpenhemmer (PPI)Mittelschwer

    Polyvalent Cations Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between FERRIPROX and other medications (e.g., antacids), or supplements containing these polyvalent cations [see Dosage and Administration ( 2.2 ) ] . (Fachinformation zu Deferipron, Arzneimittelwechselwirkungen)

  • PantoprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Pantoprazol, Arzneimittelwechselwirkungen)

  • RabeprazolProtonenpumpenhemmer (PPI)Mittelschwer

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Fachinformation zu Rabeprazol, Arzneimittelwechselwirkungen)

Geringfügige Erwähnungen (5)

  • Bictegravir, Emtricitabin und Tenofoviralafenamidantiretrovirales ArzneimittelGeringfügig

    Oral medications or supplements containing polyvalent cations (e.g., Mg, Al, Ca, Fe): Calcium or iron supplements Cation-containing antacids or laxatives Sucralfate Buffered medications ↓ bictegravir Antacids containing Al/Mg : Take BIXLENVO at least 2 hours before or 6 hours after taking antacids containing Al/Mg. (Fachinformation zu Bictegravir, Emtricitabin und Tenofoviralafenamid, Arzneimittelwechselwirkungen)

  • DemeclocyclinTetracyclin-AntibiotikumGeringfügig

    Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and by iron-containing preparations. (Fachinformation zu Demeclocyclin, Arzneimittelwechselwirkungen)

  • Dolutegravirantiretrovirales ArzneimittelGeringfügig

    Oral calcium or iron supplements, including multivitamins containing calcium or iron a ↓Dolutegravir When taken with food, TIVICAY and supplements or multivitamins containing calcium or iron can be taken at the same time. (Fachinformation zu Dolutegravir, Arzneimittelwechselwirkungen)

  • DoxycyclinTetracyclin-AntibiotikumGeringfügig

    Absorption of tetracyclines, including doxycycline hyclate is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron-containing preparations. (Fachinformation zu Doxycyclin, Arzneimittelwechselwirkungen)

  • MinocyclinTetracyclin-AntibiotikumGeringfügig

    Antacids and Iron Preparations Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium and iron-containing preparations. (Fachinformation zu Minocyclin, Arzneimittelwechselwirkungen)

Prüfen Sie Deferipron gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.